title: [Relevance of fluoroquinolone use in Lorraine: results of the first survey].
abstract: OBJECTIVE
  The Antibiolor network assessed the good use of fluoroquinolones (FQ) in the French Lorraine region by a relevance review.
  
  
  METHODS
  At the beginning of 2008, the experts in voluntary hospitals filled out a standard card mentioning the indication, FQ name, route, and duration according to prescriptions in the last 3 months. Two experts checked the relevance of prescriptions according to the local Antibioguide, and determined a score of therapeutic adequacy index for each card. Each establishment was given its results. Corrective measures were adopted at a meeting of the regional antibiotics commission in January 2009.
  
  
  RESULTS
  One hundred and twenty-four units (61 medical, 33 surgical, 17 ICU, 2 ER, 11 long-stay hospital) in 28 hospitals filled 1538 cards. The most frequent indications were: pulmonary (632), urinary (445), digestive (130). The FQ indication was non-conform for 36% of the cards (n=554). When the FQ indication was justified (984 cards), the chosen molecule was non-conform in 222 cases (23%), dose in 115 cases (12%), duration in 250 cases (25%), and route of administration in 83 cases (8%). The prescriptions were entirely conform for 425 cards (28%).
  
  
  CONCLUSIONS
  The Lorraine hospitals massively took part in this study. The second survey will use the same methodology. The objective will be to reduce the number of unjustified FQ prescriptions and to increase the number of conform cards.
authors.affiliation: Maladies infectieuses et tropicales, hôpitaux de Brabois, CHU de Nancy, allée du Morvan, Vandoeuvre-les-Nancy, France. thanh.lecompte@wanadoo.fr
authors.forename: T
authors.initials: T
authors.lastname: Doco-Lecompte
authors.forename: B
authors.initials: B
authors.lastname: Demoré
authors.forename: C
authors.initials: C
authors.lastname: Burty
authors.forename: G
authors.initials: G
authors.lastname: Rondelot
authors.forename: P
authors.initials: P
authors.lastname: Scheid
authors.forename: P
authors.initials: P
authors.lastname: Zuck
authors.forename: L
authors.initials: L
authors.lastname: Simon
authors.forename: L
authors.initials: L
authors.lastname: Letranchant
authors.forename: C
authors.initials: C
authors.lastname: Robert
authors.forename: E
authors.initials: E
authors.lastname: Frentiu
authors.forename: M
authors.initials: M
authors.lastname: Petitfrère
authors.forename: B
authors.initials: B
authors.lastname: Simplot
authors.forename: S
authors.initials: S
authors.lastname: Bevilacqua
authors.forename: C
authors.initials: C
authors.lastname: Voltz
authors.forename: C
authors.initials: C
authors.lastname: Rabaud
authors.forename: T
authors.initials: T
authors.lastname: May
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000592:standards; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005602:France; D006801:Humans; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones